Remicade (Infliximab) for Psoriasis

Overview
Remicade is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of psoriatic arthritis and for chronic severe plaque psoriasis in people who are candidates for systemic therapy. Remicade may be referred to by its drug name, infliximab.

Remicade is a biologic drug. It is a genetically engineered antibody used by the immune system to identify and neutralize substances. Remicade is believed to work by attaching to tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks. Remicade binds to TNF-α and prevents it from signaling the immune system to attack the connective tissues.

How do I take it?
Remicade is administered as an intravenous infusion every four or eight weeks after initial loading doses.

Remicade is available in vial form.

Side effects
The FDA-approved label for Remicade lists common side effects including – infections (e.g. upper respiratory, sinusitis, and pharyngitis), infusion-related reactions, headache, and abdominal pain.

Rare but serious side effects listed for Remicade include serious bacterial, viral, and fungal infections, cancer, Hepatitis B, heart failure, blood disorders, allergic reactions, lupus-like syndrome, and demyelinating disease.

For more details about this treatment, visit:

Remicade — Janssen
https://www.remicade.com